Western Australian Institute for Medical Research (WAIMR)


http://www.waimr.uwa.edu.au

State-Wide Facilities and Studies

WAIMR plays an important role for the Western Australian community by housing a number of state-wide facilities and conducting a number of state-wide studies. These include:

Australian Genome Research Facility (AGRF)

The Australian Genome Research Facility has recently opened laboratories in Perth, at the Western Australian Institute for Medical Research. It was established in 1997 as part of a Commonwealth Government Major National Research Facility (MNRF) Program. After demonstrating the ability of AGRF to enable research in Australia, the Australian Government continues funding the facility through Bioplatforms Australia (BPA) under the National Collaborative Research Infrastructure Strategy (NCRIS) Programme. AGRF is now operating laboratories in five states.

AGRF is a not for profit organisation and provides genomics services and solutions to researchers across Australia. AGRF Perth provides sequencing and fragment analysis services to the local Western Australian research community and also enables access to all AGRF's broad range of genomics services. These include:

  • Next-generation sequencing
  • SNP Genotyping
  • Gene Expression
  • Epigenomics and Structural genomics
  • Nucleic Acid Extraction
  • Plant Growth and Stress services

The AGRF range of services is unique in Australia and recognised internationally with AGRF's accreditation by NATA to the ISO/IEC17025:2005 Quality Standard.

For more information visit www.agrf.org.au.

Lotterywest State Biomedical Research Facility

The Lotterywest State Biomedical Research Facility was established with a generous grant from Lotterywest. The Facility allows the medical research community access to state-of-the-art microarray instrumentation and services, utilising the Affymetrix GeneChip technology.

WAIMR has signed a new management deal with Perth-based company Proteomics International that will see the company operate and manage the new proteomics equipment located in the Lotterywest State Biomedical Research Facility.

The deal ensures the Facility's new state-of-the-art research equipment will be utilised to maximum capacity. Proteomics is a burgeoning new research area that WA has the capacity to drive internationally. It is an exciting new field of science that promises to speed-up drug discovery and development to tackle disease.

For more information visit www.proteomics.com.au.

Monoclonal Antibody Facility

With the support of UWA and the Wind Over Water Foundation, WAIMR has established the WA Monoclonal Antibody Facility. Headed by Kathy Davern, it is the first of its kind in WA.

The state-of-the-art facility is now producing pure antibodies needed for medical or research purposes. It has been embraced by researchers as well as biotechnology companies, which now have access to the custom-made antibodies necessary to develop new products such as diagnostic tools.

WAIMR believes the Monoclonal Antibody Facility provides a unique opportunity for WA to become a major player in the international pharmaceutical industry. Globally, the biotechnology industry is booming, with the production of antibodies for use in the medical field and research arena worth more than $10 billion annually.

Monoclonal antibodies have been used to successfully treat breast cancer, lymphoma, rheumatoid arthritis, asthma, leukaemia and in transplants to minimise the chances of organ rejection.

For more information visit www.absolutions.org.au.

WA DNA Bank

The Western Australian DNA Bank (WADB) is a world-class resource helping WA and Australian medical researchers to more easily conduct larger-scale health studies and so speed up their search for life-changing discoveries.

The project, funded by the Federal Government through the National Health and Medical Research Council of Australia, provides scientists with a state-of-the-art facility to store DNA samples needed to undertake critical medical research into common diseases such as breast cancer, colorectal cancer, and heart disease.

The WADB brings large numbers of DNA samples under one roof in a highly secure way, and because of this, it is of extraordinary value to the nation's scientific community.

By helping to aid Australian researchers' access to larger collections of DNA samples, which can often be expensive and time consuming to collect, the outcomes of their studies are likely to be more reliable, therefore having an increased impact on the health of our community.

For more information visit www.wadb.org.au.